Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 101

Sort by

Sort Order Select

Journal Articles

IDH2 Mutations from Clonal Hematopoiesis and Acquired IKZF1 Deletions Define a Novel B-ALL Subtype after Lenalidomide Therapy for Multiple Myeloma

Blood (2024) 144 (Supplement 1): 631.

https://doi.org/10.1182/blood-2024-199601

Published: 2024

Journal Articles

Update on GMALL Trial 08/2013 Shows Durable Favorable Outcome of Newly Diagnosed Adult Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ALL) with Imatinib, Dose-Reduced Induction Followed By Stem Cell Transplantation

Heike Pfeifer, Fabian Lang, Walter Fiedler, Matthias Stelljes, Folker Schneller, Björn Steffen, Boris Böll, Andreas Viardot, Christoph Faul, Lino L. Teichmann, Hendrik Poeck, Joerg Westermann, Kerstin Schäfer-Eckart, Thomas Heinicke, Thomas Burmeister, Stefan Schwartz, Monika Brueggemann, Hubert Serve, Nicola Goekbuget

Blood (2024) 144 (Supplement 1): 840.

https://doi.org/10.1182/blood-2024-201217

Published: 2024

Journal Articles

Drug Sensitivity and Treatment Response Are Modulated By the Cell of Origin, the Underlying Gene Fusion, and Patient Age in KMT2A -Rearranged BCP-ALL

Blood (2024) 144 (Supplement 1): 318.

https://doi.org/10.1182/blood-2024-199017

Published: 2024

Journal Articles

Chemotherapy or Stem Cell Transplantation in Adult High Risk Ph/BCR::ABL1-Negative ALL Patients with Early MRD Negativity: Results of the Randomized GMALL Trial 08/2013

Blood (2024) 144 (Supplement 1): 961.

https://doi.org/10.1182/blood-2024-199060

Published: 2024

Journal Articles

C/EBP Family Member Gene Fusions and Cooperating Genomic Events Define Two Distinct Molecular Sub-Groups in Adult B Precursor ALL

Blood (2024) 144 (Supplement 1): 1458.

https://doi.org/10.1182/blood-2024-211088

Published: 2024

Journal Articles

Integrateall, a Machine Learning Pipeline for Multi-Level Data Extraction from RNA-Seq Profiles Unravels Novel Drivers and Systematic Subtype Classification in B-Cell Precursor ALL

Nadine Wolgast, Thomas Beder, Mayukh Mondal, Wencke Walter, Stephan Hutter, Sonja Bendig, Jan Kässens, Björn-Thore Hansen, Katharina Iben, Barz Malwine, Martin Neumann, Nicola Goekbuget, Claudia Haferlach, Monika Brüggemann, Claudia D Baldus, Alina M. Hartmann, Lorenz Bastian

Blood (2024) 144 (Supplement 1): 4213.

https://doi.org/10.1182/blood-2024-199557

Published: 2024

Journal Articles

Outcome of Patients with Hematologic or Molecular Relapsed/Refractory (R/R) Acute T- Lymphoblastic Leukemia - Data from the GMALL Study Group

Anjali Cremer, Maher Hanoun, Ralph Wäsch, Simon Raffel, Klaus Wethmar, Andreas Viardot, Walter Fiedler, Knut Wendelin, Lore Marretta, Wolfram Jung, Roland Schroers, Vladan Vucinic, Monika Brüggemann, Stefan Schwartz, Hubert Serve, Nicola Goekbuget

Blood (2024) 144 (Supplement 1): 1436.

https://doi.org/10.1182/blood-2024-202270

Published: 2024

Journal Articles

Data-Informed, Refined Immunophenotypic Classification of Adult T-Lineage Acute Lymphoblastic Leukemia

Stefan Habringer, Iva Todorova, Frederik Herzberg, Daniel Steiert, Arik Horne, Thomas Burmeister, Simon Haas, Ulrich Keller, Monika Brüggemann, Michaela Kotrova, Claudia D Baldus, Nicola Goekbuget, Martin Neumann, Stefan Schwartz

Blood (2024) 144 (Supplement 1): 1460.

https://doi.org/10.1182/blood-2024-202301

Published: 2024

Journal Articles

Molecular Subtypes in BCR::ABL1 -Positive ALL Are Defined By Cellular Origins and Cooperating Genomic Events

Blood (2023) 142 (Supplement 1): 843.

https://doi.org/10.1182/blood-2023-187315

Published: 2023

Journal Articles

Dose Reduced Chemotherapy in Sequence with Blinatumomab for Newly Diagnosed Older Patients with Ph/BCR::ABL Negative B-Precursor Adult Lymphoblastic Leukemia (ALL): Preliminary Results of the GMALL Bold Trial

Nicola Goekbuget, Stefan Schwartz, Christoph Faul, Max S. Topp, Marion Subklewe, Andrea Renzelmann, Andrea Stoltefuss, Bernd Hertenstein, Anne Wilke, Simon Raffel, Nadja Jäkel, Vladan Vucinic, Dirk Markus Niemann, Lena Reiser, Hubert Serve, Monika Brüggemann, Andreas Viardot

Blood (2023) 142 (Supplement 1): 964.

https://doi.org/10.1182/blood-2023-180472

Published: 2023

Journal Articles

CNS Irradiation in Adult De Novo B-Precursor ALL / Lbl: Results of the Randomized GMALL T rial 08/2013 Indicate Potential Antileukemic Efficacy

Blood (2023) 142 (Supplement 1): 828.

https://doi.org/10.1182/blood-2023-179442

Published: 2023

Journal Articles

Reshaping MRD Detection Strategies: Next-Generation Sequencing and High DNA Input Identify Previously Missed Measurable Residual Disease in Peripheral Blood of B-Cell Precursor Acute Lmyphoblastic Leukemia

Sonja Bendig, Sandra Bufe, Birgit Fricke, Constantin Proske, Nikos Darzentas, Britta Kehden, Guranda Chitadze, Claudia D Baldus, Michaela Kotrova, Nicola Goekbuget, Monika Brüggemann

Blood (2023) 142 (Supplement 1): 4354.

https://doi.org/10.1182/blood-2023-174458

Published: 2023

Journal Articles

Venetoclax and Blinatumomab for Adult Patients with Relapsed/Refractory or MRD Positive Ph-Negative B-Precursor ALL: First Results of the GMALL-Bliven Trial

Lars Fransecky, Walter Fiedler, Christoph Röllig, Tim Sauer, Simon Raffel, Winfried Alsdorf, Lisa Heberling, Kumaran Nagarajan, Britta Steer, Philipp Nakov, Björn Steffen, Dorothee Deckbar, Sonja Bendig, Lorenz Bastian, Martin Neumann, Monika Brueggemann, Nicola Goekbuget, Claudia D Baldus

Blood (2023) 142 (Supplement 1): 1502.

https://doi.org/10.1182/blood-2023-173937

Published: 2023

Journal Articles

Outcome of 841 Older Patients (>55 yrs) with Newly Diagnosed Ph/BCR-ABL Negative ALL Prospectively Treated According to Pediatric-Based, Age-Adapted GMALL Protocols

Blood (2022) 140 (Supplement 1): 121–123.

https://doi.org/10.1182/blood-2022-158934

Published: 2022

Journal Articles

Blinatumomab Alternating With Low-Intensity Chemotherapy (CT) Treatment for Older Adults With Newly Diagnosed Philadelphia (Ph)-Negative B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) is Well Tolerated and Efficacious: Safety Run-In Results for the Phase 3 Randomized Controlled Golden Gate Study

Elias Jabbour, Ibrahim Aldoss, Shaun Fleming, Ashish Bajel, Paul Cannell, Monika Brüggemann, Gerhard Zugmaier, Joan Morris, Yuqi Chen, Sonny Powar, Hansen Wong, Björn Steffen, Hagop Kantarjian, Nicola Goekbuget

Blood (2022) 140 (Supplement 1): 6134–6136.

https://doi.org/10.1182/blood-2022-156080

Published: 2022

Journal Articles

Inotuzumab Ozogamicin Induction Followed By Standard Chemotherapy Yields High Remission Rates and Promising Survival in Older (>55 Years) Patients with De Novo B-Lymphoblastic Leukemia (GMALL-Initial1 Trial)

Blood (2022) 140 (Supplement 1): 510–512.

https://doi.org/10.1182/blood-2022-162235

Published: 2022

Journal Articles

A Multi-Cohort Gene Expression Classifier (ALLCatchR) Identifies B-Precursor ALL Subtypes and Their Developmental Trajectories across Age Groups

Blood (2022) 140 (Supplement 1): 1053–1055.

https://doi.org/10.1182/blood-2022-163311

Published: 2022

Journal Articles

Results of the Risk-Adapted, MRD-Stratified GMALL Trial 08/2013 in 281 T-ALL / T-Lbl Patients: Excellent Outcome of Standard Risk Thymic T-ALL

Blood (2022) 140 (Supplement 1): 115–117.

https://doi.org/10.1182/blood-2022-158381

Published: 2022

Journal Articles

Expression of CD20 Affects Early MRD Response to Rituximab in Adult B Cell Precursor Lymphoblastic Leukemia of the GMALL 08/2013 Trial

Monika Szczepanowski, Johanna Richter, Miriam Kelm, Heiko Trautmann, Britta Kehden, Matthias Ritgen, Christoph Faul, Kathrin Nachtkamp, Björn Steffen, Andreas Viardot, Johannes Gärtner, Johannes Duell, Claudia D. Baldus, Stefan Schwartz, Nicola Goekbuget, Monika Brüggemann

Blood (2021) 138 (Supplement 1): 2301.

https://doi.org/10.1182/blood-2021-150375

Published: 2021

Journal Articles

Final Induction Therapy Results of an Open Label Phase II Study Using Inotuzumab Ozogamicin for Induction Therapy, Followed By a Conventional Chemotherapy Based Consolidation and Maintenance Therapy in Patients Aged 56 Years and Older with Acute B-Lymphoblastic Leukemia (INITIAL-1 trial)

Blood (2021) 138 (Supplement 1): 2300.

https://doi.org/10.1182/blood-2021-145553

Published: 2021

NARROW

IDH2 Mutations from Clonal Hematopoiesis and Acquired IKZF1 Deletions Define a Novel B-ALL Subtype after Lenalidomide Therapy for Multiple Myeloma

Update on GMALL Trial 08/2013 Shows Durable Favorable Outcome of Newly Diagnosed Adult Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ALL) with Imatinib, Dose-Reduced Induction Followed By Stem Cell Transplantation

Drug Sensitivity and Treatment Response Are Modulated By the Cell of Origin, the Underlying Gene Fusion, and Patient Age in KMT2A -Rearranged BCP-ALL

Chemotherapy or Stem Cell Transplantation in Adult High Risk Ph/BCR::ABL1-Negative ALL Patients with Early MRD Negativity: Results of the Randomized GMALL Trial 08/2013

C/EBP Family Member Gene Fusions and Cooperating Genomic Events Define Two Distinct Molecular Sub-Groups in Adult B Precursor ALL

Integrateall, a Machine Learning Pipeline for Multi-Level Data Extraction from RNA-Seq Profiles Unravels Novel Drivers and Systematic Subtype Classification in B-Cell Precursor ALL

Outcome of Patients with Hematologic or Molecular Relapsed/Refractory (R/R) Acute T- Lymphoblastic Leukemia - Data from the GMALL Study Group

Data-Informed, Refined Immunophenotypic Classification of Adult T-Lineage Acute Lymphoblastic Leukemia

Molecular Subtypes in BCR::ABL1 -Positive ALL Are Defined By Cellular Origins and Cooperating Genomic Events

Dose Reduced Chemotherapy in Sequence with Blinatumomab for Newly Diagnosed Older Patients with Ph/BCR::ABL Negative B-Precursor Adult Lymphoblastic Leukemia (ALL): Preliminary Results of the GMALL Bold Trial

CNS Irradiation in Adult De Novo B-Precursor ALL / Lbl: Results of the Randomized GMALL T rial 08/2013 Indicate Potential Antileukemic Efficacy

Reshaping MRD Detection Strategies: Next-Generation Sequencing and High DNA Input Identify Previously Missed Measurable Residual Disease in Peripheral Blood of B-Cell Precursor Acute Lmyphoblastic Leukemia

Venetoclax and Blinatumomab for Adult Patients with Relapsed/Refractory or MRD Positive Ph-Negative B-Precursor ALL: First Results of the GMALL-Bliven Trial

Outcome of 841 Older Patients (>55 yrs) with Newly Diagnosed Ph/BCR-ABL Negative ALL Prospectively Treated According to Pediatric-Based, Age-Adapted GMALL Protocols

Inotuzumab Ozogamicin Induction Followed By Standard Chemotherapy Yields High Remission Rates and Promising Survival in Older (>55 Years) Patients with De Novo B-Lymphoblastic Leukemia (GMALL-Initial1 Trial)

A Multi-Cohort Gene Expression Classifier (ALLCatchR) Identifies B-Precursor ALL Subtypes and Their Developmental Trajectories across Age Groups

Results of the Risk-Adapted, MRD-Stratified GMALL Trial 08/2013 in 281 T-ALL / T-Lbl Patients: Excellent Outcome of Standard Risk Thymic T-ALL

Expression of CD20 Affects Early MRD Response to Rituximab in Adult B Cell Precursor Lymphoblastic Leukemia of the GMALL 08/2013 Trial

Final Induction Therapy Results of an Open Label Phase II Study Using Inotuzumab Ozogamicin for Induction Therapy, Followed By a Conventional Chemotherapy Based Consolidation and Maintenance Therapy in Patients Aged 56 Years and Older with Acute B-Lymphoblastic Leukemia (INITIAL-1 trial)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only